437 related articles for article (PubMed ID: 25901683)
21. A Novel Inhibitor Targets Both Wnt Signaling and ATM/p53 in Colorectal Cancer.
Cheng J; Dwyer M; Okolotowicz KJ; Mercola M; Cashman JR
Cancer Res; 2018 Sep; 78(17):5072-5083. PubMed ID: 30032112
[TBL] [Abstract][Full Text] [Related]
22. Antagonistic Effects of p53 and HIF1A on microRNA-34a Regulation of PPP1R11 and STAT3 and Hypoxia-induced Epithelial to Mesenchymal Transition in Colorectal Cancer Cells.
Li H; Rokavec M; Jiang L; Horst D; Hermeking H
Gastroenterology; 2017 Aug; 153(2):505-520. PubMed ID: 28435028
[TBL] [Abstract][Full Text] [Related]
23. The association of TP53 mutations with the resistance of colorectal carcinoma to the insulin-like growth factor-1 receptor inhibitor picropodophyllin.
Wang Q; Wei F; Lv G; Li C; Liu T; Hadjipanayis CG; Zhang G; Hao C; Bellail AC
BMC Cancer; 2013 Nov; 13():521. PubMed ID: 24182354
[TBL] [Abstract][Full Text] [Related]
24. The status of p53 in the metastatic progression of colorectal cancer.
Heide I; Thiede C; Sonntag T; de Kant E; Neubauer A; Jonas S; Peter FJ; Neuhaus P; Herrmann R; Huhn D; Rochlitz CF
Eur J Cancer; 1997 Jul; 33(8):1314-22. PubMed ID: 9301461
[TBL] [Abstract][Full Text] [Related]
25. Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.
Zhang S; Zhou L; Hong B; van den Heuvel AP; Prabhu VV; Warfel NA; Kline CL; Dicker DT; Kopelovich L; El-Deiry WS
Cancer Res; 2015 Sep; 75(18):3842-52. PubMed ID: 26294215
[TBL] [Abstract][Full Text] [Related]
26. The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity.
Xie Y; Zhu S; Song X; Sun X; Fan Y; Liu J; Zhong M; Yuan H; Zhang L; Billiar TR; Lotze MT; Zeh HJ; Kang R; Kroemer G; Tang D
Cell Rep; 2017 Aug; 20(7):1692-1704. PubMed ID: 28813679
[TBL] [Abstract][Full Text] [Related]
27. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.
Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B
J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005
[TBL] [Abstract][Full Text] [Related]
28. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas.
Donehower LA; Soussi T; Korkut A; Liu Y; Schultz A; Cardenas M; Li X; Babur O; Hsu TK; Lichtarge O; Weinstein JN; Akbani R; Wheeler DA
Cell Rep; 2019 Jul; 28(5):1370-1384.e5. PubMed ID: 31365877
[TBL] [Abstract][Full Text] [Related]
29. The p53-inducible CLDN7 regulates colorectal tumorigenesis and has prognostic significance.
Hou Y; Hou L; Liang Y; Zhang Q; Hong X; Wang Y; Huang X; Zhong T; Pang W; Xu C; Zhu L; Li L; Fang J; Meng X
Neoplasia; 2020 Nov; 22(11):590-603. PubMed ID: 32992138
[TBL] [Abstract][Full Text] [Related]
30. Molecular genetic studies of tumor suppressor gene regions on chromosomes 13 and 17 in colorectal tumors.
Lothe RA; Fossli T; Danielsen HE; Stenwig AE; Nesland JM; Gallie B; Børresen AL
J Natl Cancer Inst; 1992 Jul; 84(14):1100-8. PubMed ID: 1619684
[TBL] [Abstract][Full Text] [Related]
31. Combined Inactivation of TP53 and MIR34A Promotes Colorectal Cancer Development and Progression in Mice Via Increasing Levels of IL6R and PAI1.
Öner MG; Rokavec M; Kaller M; Bouznad N; Horst D; Kirchner T; Hermeking H
Gastroenterology; 2018 Dec; 155(6):1868-1882. PubMed ID: 30099074
[TBL] [Abstract][Full Text] [Related]
32. PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK.
Lu T; Zou Y; Xu G; Potter JA; Taylor GL; Duan Q; Yang Q; Xiong H; Qiu H; Ye D; Zhang P; Yu S; Yuan X; Zhu F; Wang Y; Xiong H
Oncotarget; 2016 Dec; 7(50):83017-83030. PubMed ID: 27806324
[TBL] [Abstract][Full Text] [Related]
33. RASSF10 suppresses colorectal cancer growth by activating P53 signaling and sensitizes colorectal cancer cell to docetaxel.
Guo J; Yang Y; Yang Y; Linghu E; Zhan Q; Brock MV; Herman JG; Zhang B; Guo M
Oncotarget; 2015 Feb; 6(6):4202-13. PubMed ID: 25638156
[TBL] [Abstract][Full Text] [Related]
34. Metformin Bicarbonate-Mediated Efficient RNAi for Precise Targeting of
Xu J; Liu Y; Liu S; Ou W; White A; Stewart S; Tkaczuk KHR; Ellis LM; Wan J; Lu X; He X
Nano Today; 2022 Apr; 43():. PubMed ID: 35251293
[TBL] [Abstract][Full Text] [Related]
35. CP-31398 prevents the growth of p53-mutated colorectal cancer cells in vitro and in vivo.
He X; Kong X; Yan J; Yan J; Zhang Y; Wu Q; Chang Y; Shang H; Dou Q; Song Y; Liu F
Tumour Biol; 2015 Mar; 36(3):1437-44. PubMed ID: 25663456
[TBL] [Abstract][Full Text] [Related]
36. FBXW7-mutated colorectal cancer cells exhibit aberrant expression of phosphorylated-p53 at Serine-15.
Li N; Lorenzi F; Kalakouti E; Normatova M; Babaei-Jadidi R; Tomlinson I; Nateri AS
Oncotarget; 2015 Apr; 6(11):9240-56. PubMed ID: 25860929
[TBL] [Abstract][Full Text] [Related]
37. New in silico insights into the inhibition of RNAP II by α-amanitin and the protective effect mediated by effective antidotes.
Garcia J; Carvalho AT; Dourado DF; Baptista P; de Lourdes Bastos M; Carvalho F
J Mol Graph Model; 2014 Jun; 51():120-7. PubMed ID: 24879323
[TBL] [Abstract][Full Text] [Related]
38. Transforming toxins into treatments: the revolutionary role of α-amanitin in cancer therapy.
Ning D; Xue J; Lou X; Shao R; Liu Y; Chen G
Arch Toxicol; 2024 Jun; 98(6):1705-1716. PubMed ID: 38555326
[TBL] [Abstract][Full Text] [Related]
39. Relationship between ganglioside expression and anti-cancer effects of the monoclonal antibody against epithelial cell adhesion molecule in colon cancer.
Kwak DH; Ryu JS; Kim CH; Ko K; Ma JY; Hwang KA; Choo YK
Exp Mol Med; 2011 Dec; 43(12):693-701. PubMed ID: 22033101
[TBL] [Abstract][Full Text] [Related]
40. High Expressions of CUL4A and TP53 in Colorectal Cancer Predict Poor Survival.
Li C; Bu J; Liao Y; Zhang J; Han J; Zhang H; Xing H; Li Z; Wu H; Liang L; Wang M; Qin W; Yang T
Cell Physiol Biochem; 2018; 51(6):2829-2842. PubMed ID: 30562757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
